Chronic Kidney Disease Market (2026-2036)

The growth of this market is mainly driven by the rising global prevalence and mortality of chronic kidney disease, growing payer pressure to slow progression to kidney failure, expanding treatment options in glomerular and rare kidney disease, increasing label expansion across established kidney-protective agents, and strengthening guideline support for kidney-protective pharmacotherapy. However, loss of exclusivity across the largest kidney-protective franchises, volume-based procurement and price erosion in China, maximum fair price implementation under the Medicare Drug Price Negotiation Program, and low diagnosis and testing rates restrain the growth of this market.

Furthermore, closing the treatment gap among guideline-eligible patients, the growing branded opportunity in non-diabetic chronic kidney disease, expanding quality measurement of kidney health evaluation, and emerging cell and nucleic acid therapies are expected to offer growth opportunities for the stakeholders in this market. However, reimbursement classification and bundling of oral renal drugs, generic and biosimilar erosion across renal anaemia and mineral metabolism, high attrition in chronic kidney disease drug development, limited availability and standardisation of cystatin C testing, and out-of-pocket burden in emerging markets remain major challenges impacting the growth of this market. Additionally, the growing acceptance of estimated glomerular filtration rate slope as a regulatory endpoint, rising competitive density in immunoglobulin A nephropathy, increasing adoption of race-free and cystatin C-based estimation, rising deployment of home and point-of-care albuminuria testing, and growing portfolio realignment across renal specialty companies are prominent trends in this market.

The Chronic Kidney Disease Market comprises the pharmacological treatment of chronic kidney disease and its metabolic complications, together with the tests used to detect, stage and monitor the condition. The market includes kidney-protective disease-modifying therapies covering sodium-glucose co-transporter-2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists with kidney outcome claims, renin-angiotensin system inhibitors, endothelin receptor antagonists, complement pathway inhibitors, targeted glomerular immunomodulators and vasopressin V2 receptor antagonists; complication-management therapies covering anaemia of chronic kidney disease, chronic kidney disease-mineral and bone disorder, hyperkalaemia, metabolic acidosis and chronic kidney disease-associated pruritus; and diagnosis and monitoring covering serum creatinine and estimated glomerular filtration rate, cystatin C, urine albumin-to-creatinine ratio testing, prognostic risk-stratification assays, kidney biopsy and imaging. Dialysis equipment and consumables, dialysis service delivery, kidney transplantation and transplant immunosuppression, and therapies specific to acute kidney injury are excluded. The market ecosystem extends from active pharmaceutical ingredient, peptide and biologics manufacturers to originator and specialty pharmaceutical companies, generic and biosimilar producers, diagnostics manufacturers and clinical laboratories, specialty pharmacies and distributors, payers and health technology assessment bodies, and the nephrologists, primary care prescribers and patients who diagnose and treat the condition.

The market is experiencing strong growth as chronic kidney disease moves from a condition managed by blood pressure control alone to one with multiple classes of proven kidney-protective therapy. The GBD 2023 Chronic Kidney Disease Collaborators study, published online in The Lancet on 7 November 2025, recorded 788 million adults aged 20 and above with chronic kidney disease in 2023 against 378 million in 1990, at an age-standardised prevalence of 14.2%, with stages 1 to 3 accounting for 13.9% of adults and 1.48 million deaths attributed to the condition in 2023. The KDIGO 2024 Clinical Practice Guideline, published in Kidney International at volume 105, supplement 4S, retained only six statements unchanged from its 2012 predecessor and now recommends sodium-glucose co-transporter-2 inhibitors at grade 1A across diabetic and non-diabetic chronic kidney disease above an estimated glomerular filtration rate of 20. Increasing prescribing of these classes, expanding label coverage and the arrival of branded therapy in glomerular disease are significantly increasing demand across the market.

Payer economics are further strengthening market growth, because the downstream cost of kidney failure dwarfs the cost of preventing it. Medicare spending on chronic kidney disease excluding kidney failure reached nearly USD 77 billion among beneficiaries aged 66 and above in 2021, equal to 24.1% of Medicare spending for that age group, while kidney failure accounted for a further USD 52.3 billion. Per-person Medicare spending for beneficiaries aged 66 and above was USD 28,162 with chronic kidney disease against USD 13,604 without, and mortality was 101.8 per 1,000 person-years against 46.3. More than 808,000 people in the United States live with kidney failure, of whom 68% receive dialysis and 32% hold a transplant, and global kidney replacement therapy need is projected to rise from approximately 2.6 million people in 2010 to 5.4 million by 2030. A therapy that defers that transition carries a payer value far above its acquisition cost.

Demand is being reshaped by a wave of approvals in glomerular disease, an area that carried no targeted therapy a decade ago. Novartis received traditional United States approval for Fabhalta in primary immunoglobulin A nephropathy in July 2026 after APPLAUSE-IgAN two-year results in the New England Journal of Medicine on 29 March 2026 showed an estimated glomerular filtration rate slope of negative 3.10 against negative 6.12 millilitres per minute per 1.73 square metres, 49.3% slower decline, with composite kidney failure at 21.4% against 33.5% and a hazard ratio of 0.57. Travere received approval for Filspari in focal segmental glomerulosclerosis without nephrotic syndrome in April 2026, the first approved medicine in that indication, addressing an estimated United States population above 30,000. Otsuka, Vera Therapeutics and Vertex have brought APRIL and BAFF pathway agents to approval or review, and Apellis secured the first approval in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in July 2025.

Reported market value is at the same time being compressed by genericisation and administered pricing across the largest franchises. AstraZeneca reported Farxiga product revenue of USD 3,998 million for the first half of 2026, down 11% at constant exchange rates, with second-quarter revenue down 19%, attributing the decline to United States loss of exclusivity with multiple generics launched in the quarter and to volume-based procurement in China, and reported roxadustat down 63% to USD 57 million on Chinese generic competition. Otsuka reported combined tolvaptan sales of JPY 221,910 million for the year to March 2026, down 21.1% after United States generic entry in April 2025. The Centers for Medicare & Medicaid Services set a maximum fair price of USD 178.50 per 30-day supply of Farxiga against a 2023 list price of USD 556.00 and USD 197.00 for Jardiance against USD 573.00, effective for 2026.

Another major growth driver is the scale of the untreated and undiagnosed population, which sets the headroom available from existing indications alone. The Centers for Disease Control and Prevention estimates that 14% of United States adults, approximately 37 million people, have chronic kidney disease at stages 1 to 4 and that 87% do not know they have it, with prevalence reaching 38% among adults with any diabetes and 21% among those with high blood pressure. An analysis of 192,108 patients in JAMA Network Open found albuminuria testing in only 17.5% of those with hypertension or diabetes, and an Australian primary care analysis of 114,499 adults with type 2 diabetes published in Diabetes, Obesity and Metabolism found sodium-glucose co-transporter-2 inhibitors dispensed to 14.4% of those with chronic kidney disease and 17.8% of the trial-eligible subgroup. Each additional patient identified and treated represents a long-duration therapy at guideline-recommended intensity.

At the same time, the growing use of race-free and cystatin C-based estimation, home albuminuria testing and payment-linked quality measurement is reshaping the chronic kidney disease ecosystem and creating new opportunities for diagnostics suppliers. Adoption of the 2021 CKD-EPI creatinine equation among United States laboratories reached 65.8% by March 2023 from 30.3% a year earlier, while implementation of the combined creatinine and cystatin C equation stood at only 7.3%, against KDIGO grade 1B and 1C recommendations for its use. Healthy.io received clearance for a smartphone-based home urine albumin-to-creatinine ratio test on 12 July 2022 and a validation study reported sensitivity of 96.4% and specificity of 84.2%. The Kidney Health Evaluation measure, requiring both tests annually in diabetes, has been reported within Medicare Advantage and Part D Star Ratings since 2024 across plans covering more than 200 million people.

Forecast Period

2026-2036

Base Year

2025

Estimated Year

2026

CAGR (Value)

7.4%

Market Size (Value) in 2026

USD 21.90 Billion

Market Size (Value) in 2036

USD 44.72 Billion

Segments Covered

Treatment Type, Molecule Type, Disease Stage, Route of Administration, Distribution Channel, End User

Countries Covered

North America: U.S., Canada. Europe: Germany, U.K., France, Italy, Spain, Netherlands, Nordic Countries, Russia, Rest of Europe. Asia-Pacific: China, Japan, India, South Korea, Australia & New Zealand, Taiwan, Southeast Asia, Rest of Asia-Pacific. Latin America: Brazil, Mexico, Argentina, Colombia, Rest of Latin America. Middle East & Africa: Saudi Arabia, UAE, Israel, Turkey, Egypt, South Africa, Rest of Middle East & Africa.

Key Companies